Gonorrhea Diagnostic Market Size, Share, Growth Analysis, By Type(Flow Cytometry, Diagnostic Imaging), By Application(Hospital, Personal Use), By End-User(Public Sector, Private Sector), By Region(North America, Europe) - Industry Forecast 2024-2031

The rising prevalence of the disease globally and the unmet demand for quicker diagnosis tools are likely to contribute to the considerable rise of the global gonorrhoea diagnostic market during the forecast period. The U.S. Centre for Disease Control and Prevention, or CDC, reports that the prevalence rate of gonorrhoea in recent years has been around 106 cases per million per year. 333,004 instances of gonorrhoea were reported in the United States in 2013, according to the CDC's verified statistics. The CDC estimates that more than 820000 Americans contract gonococcal infections year, yet fewer than half of these cases are reported. Each year, there are about 28000 cases reported in the UK.The variables that are anticipated to contribute to the disease's rising prevalence are a lack of knowledge about the condition and ambiguous clinical symptoms. The market will continue to rise throughout the forecast period due to the ongoing development of technologically sophisticated equipment for the analysis of lesions and the detection of disease-causing microorganisms. In addition, gonococcal bacteria are becoming more resistant as a result of the increasing non-prescription and illegal use of antibiotics including ceftriaxone, doxycycline, and azithromycine used to treat the condition. The third-line gonorrhoea medicine cephalosporin has been found to be ineffective in recent WHO assessments, particularly in Japan, Australia, and Hong Kong.